At a Glance
| Feature | Detail |
|---|---|
| Condition | Ulcerative Colitis (UC) |
| ICD-10 Code | K51 |
| CDL Status | YES — Chronic Disease List |
| PMB Coverage | Full for 5-ASA, immunomodulators, surgical management. Biologics require exceptional needs authorisation. |
| SA Prevalence | Rare but rising; estimated 8,000–20,000 SA patients (private sector) |
| Standard Treatment | 5-ASA (oral + rectal) → azathioprine → biologic or JAK inhibitor |
| Annual Cost Range | R17,100 (mild) to R158,900 (biologic) |
| Biologic Risk | YES — infliximab, vedolizumab, tofacitinib |
| Key Distinction from Crohn's | UC is potentially curable with colectomy. 5-ASA is highly effective for mild-moderate disease. |
About Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that causes continuous inflammation of the colonic mucosa (inner lining of the large bowel), always starting at the rectum and extending proximally. Unlike Crohn's Disease, UC is limited to the colon, only involves the innermost mucosal layer (not full-thickness), and is potentially curable with surgery.
UC is increasing in South Africa and sub-Saharan Africa. It affects all population groups, though historical data is biased toward the private sector. In the sub-Saharan Africa IBD network (2025), UC accounted for 58% of IBD cases — more common than Crohn's in this region.
Disease Extent Classification
UC is classified by how far it extends from the rectum:
| Classification | Extent | Notes |
|---|---|---|
| Proctitis | Rectum only | Most limited; often responds to rectal therapy alone |
| Left-sided colitis | To splenic flexure | Oral + rectal 5-ASA combination |
| Extensive / pancolitis | Beyond splenic flexure | Full colon; higher risk of severe flares |
| Total colitis | Entire colon | Highest hospitalisation and colectomy risk |
Treatment Pathway
Step 1 — 5-ASA (Mesalamine): The Cornerstone of UC Management
This is the key difference from Crohn's Disease: 5-aminosalicylate (5-ASA) therapy is highly effective in UC for both inducing and maintaining remission in mild-moderate disease. Most newly diagnosed UC patients achieve remission on combination oral + rectal 5-ASA.
- Oral mesalamine: 2.4–4.8g daily (Asacol, Salofalk, generic) — ~R500/month
- Rectal mesalamine: Suppositories (1g nightly — for proctitis) or enemas (1–4g nightly — for left-sided disease) — ~R400/month
- Sulfasalazine: Older, cheaper alternative — ~R200/month; more side effects
Topical rectal therapy is more effective than oral alone for distal UC. Many patients with proctitis can manage long-term with suppositories alone.
Step 2 — Steroid-Sparing Maintenance (Azathioprine)
For steroid-dependent patients or those who relapse frequently on 5-ASA: azathioprine (2–2.5mg/kg/day) provides effective steroid-sparing maintenance. Combined with 5-ASA. Requires monthly FBC + LFT monitoring initially.
Step 3 — Biologic Therapy / JAK Inhibitors
For moderate-severe UC failing 5-ASA and azathioprine:
- Infliximab IV (biosimilar CT-P13 preferred): IV infusion at 5mg/kg; induction at weeks 0, 2, 6; then every 8 weeks. Biosimilar (~R7,000/month); originator (~R12,000/month)
- Vedolizumab (Entyvio): Gut-selective; preferred in patients at high infection risk. IV infusion. ~R14,000/month
- Tofacitinib (Xeljanz): Oral JAK1/3 inhibitor. 10mg twice daily induction × 8 weeks; 5mg twice daily maintenance. ~R8,000/month induction, ~R4,500/month maintenance
Step 4 — Colectomy: The Curative Option
Total colectomy (removal of the entire colon) cures ulcerative colitis. This is the key distinction from Crohn's. In elective cases, an ileal pouch-anal anastomosis (IPAA / J-pouch) is constructed to restore bowel continuity. In emergency cases (toxic megacolon, perforation), end ileostomy is fashioned.
Colectomy is a major surgical procedure — two or three stages over 6–12 months. After successful IPAA construction, patients are typically disease-free without further IBD medication.
Annual Cost Estimates (Private Sector)
| Severity | Profile | Estimated Annual Cost |
|---|---|---|
| Mild | Oral + rectal 5-ASA + annual gastro review + colonoscopy | ~R17,100 |
| Moderate | 5-ASA + AZA + 4-monthly gastro + colonoscopy | ~R23,600 |
| Severe (biologic) | Infliximab biosimilar + AZA + gastro | ~R98,900–R158,900 |
The PMB and CDL Position
All schemes must fund at CDL level: 5-ASA agents (oral and rectal), azathioprine, gastroenterologist visits, colonoscopy for diagnosis and monitoring, bowel surgery (PMB).
Biologics and JAK inhibitors: NOT standard CDL formulary. Require exceptional needs authorisation. Biosimilar infliximab (CT-P13) is the preferred first biologic for severe UC in most scheme formularies.
Colectomy: PMB-funded as a surgical procedure for UC. Colorectal surgeon shortfall is the gap cover exposure.
Gap Cover Relevance
| Scenario | Gap Cover Relevance |
|---|---|
| 5-ASA + AZA management | LOW — CDL-funded |
| Biologic OOP cost | NONE — formulary issue, not gap |
| Acute severe UC hospitalisation: gastro shortfall | HIGH |
| Emergency colectomy (toxic megacolon): colorectal surgeon | VERY HIGH |
| Elective IPAA colectomy: colorectal surgeon shortfall | HIGH — staged procedure, multiple admissions |
| Colonoscopy sub-limit | MEDIUM |
The Talk to Eldon Angle
For most UC patients (mild-moderate, on 5-ASA), annual management cost is R17,000–R24,000 — entirely CDL-funded and affordable. The financial escalation points are biologic therapy (R99,000–R159,000/year) and colectomy (~R180,000–R250,000 surgical bill, curative). Unlike Crohn's, a patient who has had a successful colectomy exits the high-cost treatment pathway entirely. The surgical shortfall on colectomy — particularly on the IPAA stages — is the primary gap cover use case for UC.
Sources
- Emerging Patterns of IBD in Sub-Saharan Africa. J Crohn's Colitis, January 2025.
- Medical Aid Schemes that Cover Ulcerative Colitis. MedicalAid.co.za, 2024.
- CMS PMB Regulations — CDL: Ulcerative Colitis.
Ready to check your UC cover? Run your AURA medical aid check